Montelukast Viatris

Montelukast, the active ingredient in Montelukast Viatris, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is prescribed for the maintenance treatment of asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic airway disorders. - Asthma: improves long‑term control and reduces the frequency of wheezing episodes. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Adverse reactions may vary in frequency and severity. Common Side Effects: - Headache: mild to moderate pain often reported. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: occasional dry or productive cough. - Nausea: feeling of queasiness without vomiting. Serious or Rare Side Effects: - Angioedema: swelling of the face, lips or throat requiring urgent care. - Stevens‑Johnson syndrome: severe skin reaction with blisters and detachment. - Mood changes: depression, anxiety or suicidal thoughts. - Hepatic injury: abnormal liver function tests or hepatitis.

Safety considerations should be reviewed before initiating therapy. - Monitor liver function: assess baseline and periodic liver enzymes in patients with hepatic disease. - Assess mood changes: watch for depression, anxiety or suicidal ideation, especially in adolescents. - Use caution in severe hepatic impairment: dosage adjustment may be required. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Potential drug‑drug interactions may affect efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - Phenobarbital: can lower montelukast exposure. - St. John’s wort: may decrease effectiveness. Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation. - Theophylline: additive bronchodilator effect, observe for tachycardia. - Beta‑agonists: may increase risk of tremor or palpitations.